Presenters at the 2015 San Antonio Breast Cancer Symposium (SABCS; December 8–12, 2015) reported on the latest studies in breast cancer. Key findings are summarized below by Dr. William Gradishar, Editor-in-Chief of NEJM Journal Watch Oncology and Hematology. For more information, please visit the SABCS website (https://www.sabcs.org).
Avelumab for Locally Advanced or Metastatic Breast Cancer
Interest in immunologic checkpoint inhibitors is growing due to the demonstrated impact of these agents in tumor types such as melanoma and lung cancer. To test the clinical activity of the humanized anti–PD-L1 antibody avelumab in breast cancer, Dirix and investigators conducted the industry-sponsored, international, phase 1b JAVELIN trial (abstract S1-…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)